Record NNP B-NP O
date NN I-NP O
: : O O
2092-12-27 CD O B-DATE
MARTHA NNP B-NP B-HOSPITAL
JEFFERSON NNP I-NP I-HOSPITAL
HOSPITAL NNP I-NP I-HOSPITAL
Stephen NNP B-NP B-DOCTOR
A.N. NNP I-NP I-DOCTOR
Xayachack NNP I-NP I-DOCTOR
, , O O
M.D. NNP B-NP O
039 CD B-NP B-STREET
Will MD O I-STREET
St NNP B-NP I-STREET
Vicente NNP I-NP I-PATIENT
, , O I-PATIENT
Kadeem NNP B-NP I-PATIENT
Sandpoint NNP B-NP B-CITY
, , O O
MI NNP B-NP B-STATE
58543 CD I-NP B-ZIP
CK759182 . O B-MEDICALRECORD
( -LRB- B-NP I-PHONE
033 CD I-NP I-PHONE
) -RRB- I-NP I-PHONE
250-1408 CD I-NP I-PHONE
12-27-92 CD O B-DATE
HPI NNP B-NP O
: : O O
Kadeem NNP B-NP B-PATIENT
Vicente NNP I-NP I-PATIENT
comes VBZ B-VP O
in IN B-PP O
today NN B-NP O
for IN B-PP O
a DT B-NP O
follow-up JJ I-NP O
office NN I-NP O
visit NN I-NP O
. . O O
The DT O O
patient NN B-NP O
was VBD B-VP O
seen VBN I-VP O
by IN B-PP O
me PRP B-NP O
approximately RB B-NP O
one CD I-NP O
month NN I-NP O
ago RB B-ADVP O
as IN B-PP O
a DT B-NP O
new JJ I-NP O
patient NN I-NP O
and CC O O
whose WP$ B-NP O
primary JJ I-NP O
medical JJ I-NP O
concerns NNS I-NP O
a DT B-NP O
history NN I-NP O
of IN B-PP O
coronary JJ B-NP O
artery NN I-NP O
disease NN I-NP O
, , O O
for IN B-PP O
which WDT B-NP O
he PRP B-NP O
suffered VBD B-VP O
a DT B-NP O
" `` I-NP O
silent JJ I-NP O
heart NN I-NP O
attack NN I-NP O
" `` O O
many JJ B-NP O
years NNS I-NP O
ago RB B-ADVP O
, , O O
a DT B-NP O
history NN I-NP O
of IN B-PP O
benign JJ B-NP O
prostatic JJ I-NP O
hypertrophy NN I-NP O
, , O O
as RB B-CONJP O
well RB I-CONJP O
as IN I-CONJP O
hypertension NN B-NP O
and CC I-NP O
GERD. NNP I-NP O
As IN B-PP O
it PRP B-NP O
turns VBZ B-VP O
out RP B-ADJP O
, , O O
the DT B-NP O
patient NN I-NP O
had VBD B-VP O
been VBN I-VP O
on IN B-PP O
Zantac NNP B-NP O
for IN B-PP O
many JJ B-NP O
, , I-NP O
many JJ I-NP O
years NNS I-NP O
, , O O
the DT B-NP O
beneficial JJ B-NP O
effects NNS I-NP O
of IN B-PP O
which WDT B-NP O
were VBD B-VP O
unknown JJ B-ADJP O
. . O O
We PRP B-NP O
had VBD B-VP O
decided VBN I-VP O
as IN B-PP O
of IN B-PP O
our PRP$ B-NP O
last JJ I-NP O
meeting NN B-NP O
to TO B-VP O
stop VB I-VP O
this DT B-NP O
drug NN I-NP O
and CC O O
find VB B-VP O
out RP B-NP O
if IN B-SBAR O
he PRP B-NP O
became VBD B-VP O
symptomatic JJ B-ADJP O
. . O O
The DT O O
patient JJ B-NP O
reports NNS I-NP O
today NN B-NP O
that IN B-SBAR O
he PRP B-NP O
is VBZ B-VP O
not RB O O
symptomatic JJ B-ADJP O
, , O O
and CC O O
thus RB B-ADVP O
we PRP B-NP O
will MD B-LST O
continue VB B-VP O
to TO I-VP O
discontinue VB I-VP O
this DT B-NP O
medicine NN I-NP O
. . O O
At IN B-PP O
this DT B-NP O
point NN I-NP O
, , O O
the DT B-NP O
patient NN I-NP O
does VBZ B-LST O
not RB O O
need VB B-VP O
the DT B-NP O
addition NN I-NP O
of IN B-PP O
a DT B-NP O
proton NN I-NP O
pump NN I-NP O
inhibitor NN I-NP O
, , O O
such JJ B-PP O
as IN I-PP O
Prilosec. NNP B-NP O
With IN B-SBAR O
regard NN B-NP O
to TO B-PP O
the DT B-NP O
patient NN I-NP O
's POS B-NP O
symptoms NNS I-NP O
of IN B-PP O
benign JJ B-NP O
prostatic JJ I-NP O
hypertrophy NN I-NP O
, , O O
the DT B-NP O
patient NN I-NP O
said VBD B-VP O
that IN B-SBAR O
he PRP B-NP O
only RB B-ADVP O
has VBZ B-VP O
taken VBN I-VP O
one CD B-NP O
dose NN I-NP O
of IN B-PP O
the DT B-NP O
Hytrin NNP I-NP O
, , O O
since IN B-SBAR O
he PRP O O
wanted VBD B-VP O
to TO I-VP O
use VB I-VP O
up RP B-PRT O
all DT B-NP O
his PRP$ I-NP O
Minipress NNP I-NP O
, , O O
which WDT B-NP O
he PRP B-NP O
tool NN B-VP O
up IN B-SBAR O
until IN B-NP O
2 CD I-NP O
nights NNS I-NP O
ago RB B-ADVP O
. . O O
Thus RB B-ADVP O
it PRP B-NP O
is VBZ B-VP O
too RB B-ADJP O
early JJ I-ADJP O
to TO B-VP O
assess VB I-VP O
the DT B-NP O
efficacy NN I-NP O
of IN B-PP O
this DT B-NP O
medication NN I-NP O
. . O O
It PRP B-NP O
is VBZ B-LST O
noted VBD B-VP O
that IN O O
his PRP$ B-NP O
blood NN I-NP O
pressure NN I-NP O
was VBD B-VP O
152/74 CD B-NP O
, , O O
which WDT B-NP O
is VBZ B-VP O
better JJR B-ADJP O
than IN B-SBAR O
it PRP B-NP O
was VBD B-VP O
the DT B-NP O
last JJ I-NP O
time NN I-NP O
he PRP B-NP O
was VBD B-VP O
here RB B-ADVP O
, , O O
which WDT B-NP O
the DT B-NP O
systolic JJ I-NP O
range NN I-NP O
was VBD B-VP O
160-170 CD B-NP O
and CC O O
diastolic NN B-NP O
was VBD B-VP O
80-90 JJ B-ADJP O
. . O O
The DT B-NP O
patient NN I-NP O
reports VBZ B-VP O
no DT B-NP O
new JJ I-NP O
symptomatology NN I-NP O
other JJ O O
than IN B-PP O
occasional JJ B-NP O
fatigue NN I-NP O
, , O O
from IN B-PP O
which WDT B-NP O
he PRP B-NP O
will MD B-VP O
have VB I-VP O
to TO I-VP O
rest VB I-VP O
. . O O
The DT B-NP O
patient NN I-NP O
has VBZ B-VP O
no DT B-NP O
symptoms NNS I-NP O
of IN B-PP O
congestive JJ B-NP O
heart NN I-NP O
failure NN I-NP O
, , O O
no DT B-NP O
shortness NN I-NP O
of IN B-PP O
breath NN B-NP O
, , O O
no UH O O
ankle NN B-NP O
edema NN I-NP O
, , O O
no DT B-NP O
JVD NNP I-NP O
by IN B-PP O
observation NN B-NP O
, , O O
and CC O O
his PRP$ B-NP O
laboratory NN I-NP O
results NNS I-NP O
are VBP O O
remarkably RB B-ADJP O
normal JJ I-ADJP O
, , O O
given VBN B-VP O
his PRP$ B-NP O
medical JJ I-NP O
complaints NNS I-NP O
. . O O
The DT B-NP O
patient NN I-NP O
's POS B-LST O
cholesterol NN B-NP O
is VBZ B-VP O
190 CD B-NP O
with IN B-PP O
a DT B-NP O
slightly RB I-NP O
above IN B-PP O
average JJ B-NP O
triglycerides NNS I-NP O
. . O O
Review NNP O O
of IN B-SBAR O
systems NNS B-NP O
otherwise RB B-ADVP O
negative JJ B-ADJP O
. . O O
Physical JJ B-NP O
exam NN I-NP O
is VBZ B-VP O
not RB I-VP O
performed VBN I-VP O
at IN B-PP O
this DT B-NP O
time NN I-NP O
. . O O
Blood NN B-NP O
pressure NN I-NP O
was VBD B-VP O
152/76 CD I-VP O
on IN B-PP O
the DT B-NP O
right NN I-NP O
, , O O
152/76 CD B-NP O
on IN B-PP O
the DT B-NP O
left JJ I-NP O
, , I-NP O
temperature NN I-NP O
was VBD B-VP O
96.8 CD B-NP O
, , O O
respirations NNS B-NP O
20 CD O O
and CC O O
unlabored JJ B-NP O
, , O O
and CC O O
pulse NN B-NP O
was VBD B-VP O
70 CD B-NP O
. . O O
ASSESSMENT/PLAN NNP B-NP O
: : O O
This DT B-NP O
is VBZ B-VP O
a DT B-NP O
75 CD I-NP B-AGE
year NN I-NP O
old JJ I-NP O
man NN I-NP O
with IN B-PP O
multiple JJ B-NP O
medical JJ I-NP O
problems NNS B-NP O
coming VBG B-VP O
in IN B-PP O
for IN B-PP O
follow-up NN B-NP O
. . O O
1 LS O O
. . B-NP O
Hypertension NNP I-NP O
- : O O
the DT B-NP O
patient NN I-NP O
will MD B-VP O
stay VB I-VP O
on IN B-PP O
his PRP$ B-NP O
Zestril NNP I-NP O
and CC I-NP O
will MD B-VP O
use VB I-VP O
Hytrin NNP B-NP O
now RB B-ADVP O
, , O O
both DT B-NP O
for IN B-PP O
his PRP$ B-NP O
hypertension NN I-NP O
, , O O
as RB B-CONJP O
well RB I-CONJP O
as IN I-CONJP O
benign JJ B-NP O
prostatic JJ I-NP O
hypertrophy NN B-NP O
. . O O
The DT B-NP O
patient NN I-NP O
does VBZ B-VP O
speak VB I-VP O
of IN B-PP O
some DT B-NP O
nocturnal JJ I-NP O
dribbling NN I-NP O
, , O O
and CC O O
he PRP B-NP O
said VBD B-VP O
he PRP B-NP O
also RB B-ADVP O
has VBZ B-VP O
urge NN B-NP O
incontinence NN I-NP O
, , O O
particularly RB B-ADVP O
while IN B-SBAR O
standing VBG B-VP O
. . O O
The DT B-NP O
patient NN I-NP O
was VBD B-VP O
told VBN I-VP O
that IN B-PRT O
after IN B-PP O
a DT B-NP O
trial NN I-NP O
of IN B-PP O
Hytrin NNP B-NP O
, , O O
which WDT O O
hopefully RB B-ADVP O
can MD B-VP O
help VB I-VP O
with IN B-PP O
his PRP$ B-NP O
symptoms NNS I-NP O
of IN B-PP O
benign JJ B-NP O
prostatic JJ I-NP O
hypertrophy NN B-NP O
, , O O
that IN B-SBAR O
this DT B-NP O
urge NN I-NP O
incontinency NN I-NP O
will MD B-VP O
also RB I-VP O
be VB I-VP O
helped VBN I-VP O
. . O O
If IN O O
the DT B-NP O
patient NN I-NP O
's POS B-NP O
symptoms NNS I-NP O
continue VBP B-VP O
beyond IN B-PP O
this DT B-NP O
, , O O
he PRP B-NP O
will MD B-VP O
be VB I-VP O
referred VBN I-VP O
to TO O O
Urology NNP B-NP O
for IN B-PP O
possible JJ B-NP O
TUNA NNP I-NP O
procedure NN I-NP O
. . O O
2. DT B-NP O
BPH NNP I-NP O
- : O O
please VBP B-VP O
see VB I-VP O
above IN B-PP O
. . B-NP O
The DT B-NP O
patient NN I-NP O
will MD B-VP O
stay VB I-VP O
on IN B-PP O
Hytrin NNP B-NP O
for IN B-PP O
now RB B-NP O
. . O O
3. . O O
? . O O
coronary JJ B-NP O
artery NN I-NP O
disease NN I-NP O
- : O O
the DT B-NP O
patient NN I-NP O
's POS B-NP O
cholesterol NN I-NP O
is VBZ B-VP O
190 CD B-NP O
with IN B-PP O
a DT O O
slightly RB B-ADVP O
above IN B-PP O
average JJ B-NP O
triglycerides NNS I-NP O
, , O O
which WDT B-NP O
is VBZ B-VP O
more RBR I-VP O
than IN B-PP O
acceptable JJ B-NP O
for IN B-PP O
this DT B-NP O
gentleman NN I-NP O
. . O O
I PRP B-NP O
do VBP B-VP O
not RB I-VP O
have VB I-VP O
an DT B-NP O
HDL NNP I-NP O
in IN B-PP O
which WDT B-NP O
to TO B-VP O
judge VB I-VP O
his PRP$ B-NP O
ratio NN B-NP O
, , O O
but CC O O
I PRP B-NP O
was VBD B-VP O
by IN B-PP O
the DT B-NP O
patient NN I-NP O
before IN B-PP O
that IN B-SBAR O
it PRP B-NP O
runs VBZ B-VP O
in IN B-PP O
the DT B-NP O
high JJ I-NP O
40s NNS I-NP O
MARTHA NNP B-NP B-HOSPITAL
JEFFERSON NNP I-NP I-HOSPITAL
HOSPITAL NNP I-NP I-HOSPITAL
Stephen NNP B-NP B-DOCTOR
A.N. NNP I-NP I-DOCTOR
Xayachack NNP I-NP I-DOCTOR
, , O O
M.D. NNP B-NP O
476 CD B-NP B-STREET
Will MD O I-STREET
St NNP B-NP I-STREET
Vicente NNP I-NP I-PATIENT
, , O I-PATIENT
Kadeem NNP B-NP I-PATIENT
Sandpoint NNP B-NP B-CITY
, , O O
MI NNP B-NP B-STATE
58543 CD I-NP B-ZIP
CK759182 . O B-MEDICALRECORD
( -LRB- B-NP I-PHONE
033 CD I-NP I-PHONE
) -RRB- I-NP I-PHONE
250-1408 CD I-NP I-PHONE
12-27-92 CD O B-DATE
PAGE NN B-NP O
2 CD I-NP O
or CC O O
low JJ B-NP O
50s NNS I-NP O
. . O O
Therefore RB O O
this DT B-NP O
will MD B-VP O
be VB I-VP O
an DT B-NP O
acceptable JJ I-NP O
ratio NN I-NP O
without IN B-PP O
therapy NN B-NP O
. . O O
I PRP B-NP O
will MD B-VP O
get VB I-VP O
a DT B-NP O
fasting JJ I-NP O
lipid NN I-NP O
on IN B-PP O
the DT B-NP O
patient NN I-NP O
probably RB B-ADVP O
in IN B-PP O
about IN B-PP O
6 CD B-NP O
months NNS I-NP O
, , O O
and CC O O
if IN B-SBAR O
there EX B-NP O
is VBZ B-VP O
any DT B-NP O
derangement NN I-NP O
in IN B-PP O
his PRP$ B-NP O
profile NN I-NP O
, , O O
he PRP B-NP O
will MD B-VP O
be VB I-VP O
put VBN I-VP O
on IN B-PP O
an DT B-NP O
antilipid JJ I-NP O
drug NN I-NP O
. . O O
4 LS O O
. . O O
GI VB B-VP O
- : O O
at IN B-PP O
this DT B-NP O
point NN I-NP O
his PRP$ B-NP O
GERD NNP I-NP O
symptoms NNS I-NP O
have VBP B-VP O
not RB I-VP O
returned VBN I-VP O
, , O O
and CC O O
what WP B-NP O
I PRP B-NP O
will MD B-VP O
attempt VB I-VP O
to TO I-VP O
do VB I-VP O
is VBZ B-VP O
to TO B-VP O
keep VB I-VP O
him PRP B-NP O
off RP B-VP O
his PRP$ B-NP O
H2 NNP I-NP O
blockers NNS I-NP O
at IN B-PP O
this DT B-NP O
point NN B-NP O
. . O O
Should MD O O
his PRP$ B-NP O
symptoms NNS I-NP O
return NN I-NP O
, , O O
the DT B-NP O
patient NN I-NP O
most RBS B-NP O
likely JJ I-NP O
will MD B-VP O
be VB I-VP O
placed VBN B-VP O
on IN B-PP O
Prilosec. NNP B-NP O
I PRP B-NP O
will MD B-VP O
seen VBN I-VP O
him PRP B-NP O
in IN B-PP O
one CD B-NP O
month NN I-NP O
for IN B-PP O
follow-up JJ B-NP O
, , O O
primarily RB B-ADVP O
for IN B-PP O
evaluation NN B-NP O
of IN B-PP O
his PRP$ B-NP O
use NN I-NP O
of IN B-PP O
Hytrin NNP B-NP O
. . O O
Stephen NNP B-NP B-DOCTOR
A.N. NNP I-NP I-DOCTOR
Xayachack NNP I-NP I-DOCTOR
, , O O
M.D. NNP B-NP O
KT:TR:9254 . O B-IDNUM
DD NNP B-NP O
: : O O
12-27-92 CD O B-DATE
DT NNP B-NP O
: : O O
01-01-93 CD O B-DATE
DV NNP B-NP O
: : O O
12-27-92 CD O B-DATE
******** NN B-NP O
Approved NNP I-NP O
but CC O O
not RB B-VP O
reviewed VBN I-VP O
by IN B-PP O
Attending VBG B-VP O
Provider NNP B-NP O
******** . O O
